首页|益心舒胶囊治疗冠心病心绞痛有效性及安全性的Meta分析

益心舒胶囊治疗冠心病心绞痛有效性及安全性的Meta分析

扫码查看
目的:系统评价益心舒胶囊联合常规西药治疗冠心病心绞痛的疗效和安全性.方法:检索相关数据库从建立以来到2021年12月收录的有关益心舒胶囊联合常规西药治疗冠心病心绞痛的临床随机对照试验(RCTs),根据纳入和排除标准选择益心舒胶囊联合西药治疗冠心病心绞痛的RCTs,并使用Review Manager 5.3软件进行Meta分析.结果:共纳入22项RCTs,总共3 238名患者,Meta分析结果显示,益心舒胶囊联合常规西药能有效提高临床疗效[RR=1.20,95%CI(1.15,1.25)]、降低心绞痛的发生频率[MD=-1.56,95%CI(-2.42,-0.70)]、减少心绞痛持续时间[MD=-1.26,95%CI(-1.87,-0.65)]、提高心电图疗效[RR=1.19,95%CI(1.10,1.29)]、改善临床症状(①胸痛[RR=1.15,95%CI(1.07,1.24)]、②胸闷[RR=2.52,95%CI(1.58,4.02)]、③心悸[RR=1.30,95%CI(1.19,1.41)]、④乏力[RR=1.42,95%CI(1.19,1.69)]、⑤气短[RR=1.35,95%CI(1.26,1.44))、改善心率[MD=-3.66,95%CI(-6.61,-0.71)]、改善收缩压[MD=-4.60,95%CI(-9.55,0.35)]、改善舒张压[MD=-1.14,95%CI(-2.43,0.14)]、调节血清总胆固醇(TC)[MD=-0.87,95%CI(-1.46,-0.28)],调节三酰甘油(TG)[MD=-0.19,95%CI(-0.41,0.02)],增加高密度脂蛋白(HDL-C)[MD=0.31,95%CI(0.25,0.37)],降低低密度脂蛋白(LDL-C)[MD=-0.71,95%CI[-1.09,-0.34]].试验组和对照组之间的不良反应发生率没有显著差异.结论:益心舒胶囊联合常规西药治疗冠心病心绞痛具有一定的临床疗效,值得广大医师临床验证.
Efficacy and Safety of Yixinshu(益心舒)Capsule in Treatment of Angina Pectoris in Coronary Heart Disease:A Meta-Analysis
Objective:To systematically evaluate the efficacy and safety of Yixinshu(益心舒)Capsule combined with conventional western medi-cine in the treatment of angina pectoris in coronary heart disease.Methods:Databases such as China National Knowledge Infrastructure(CNKI),Wanfang Data,VIP,SinoMed,PubMed,Web of Science and The Cochrane Library were retrieved from the inception to December 2021.And the clinical randomized controlled trials(RCTs)of Yixinshu Capsule combined with conventional western medicine in the treat-ment of angina pectoris in coronary heart disease were included according to the inclusion and exclusion criteria.Meta-analysis was performed using Review Manager 5.3.Results:A total of 22 RCTs were included,involving 3 238 patients.The Meta-analysis showed that Yixinshu Capsule combined with conventional western medicine exhibited effects in the following aspects:improving the clinical efficacy[RR=1.20,95%CI(1.15,1.25)],reducing the frequency of angina pectoris[MD=-1.56,95%CI(-2.42,-0.70)],shortening the duration of angina pectoris[MD=-1.26,95%CI(-1.87,-0.65)],enhancing the efficacy of electrocardiogram[RR=1.19,95%CI(1.10,1.29)],relieving the clinical symptoms[including chest pain[RR=1.15,95%CI(1.07,1.24)],chest tightness[RR=2.52,95%CI(1.58,4.02)],palpitation[RR=1.30,95%CI(1.19,1.41)],weakness[RR=1.42,95%CI(1.19,1.69)],and shortness of breath[RR=1.35,95%CI(1.26,1.44)]],improving heart rate[MD=-3.66,95%CI(-6.61,-0.71)],systolic blood pressure[MD=-4.60,95%CI(-9.55,0.35)]and dias-tolic blood pressure[MD=-1.14,95%CI(-2.43,0.14)],regulating serum total cholesterol(TC)[MD=-0.87,95%CI(-1.46,-0.28)]and triacylglycerol(TG)[MD=-0.19,95%CI(-0.41,0.02)],increasing high-density lipoprotein cholesterol(HDL-C)[MD=0.31,95%CI(0.25,0.37)],and decreasing low-density lipoprotein cholesterol(LDL-C)[MD=-0.71,95%CI(-1.09,-0.34)].There was no significant difference in the incidence of adverse reactions between the experimental group and the control group.Conclusion:Yixinshu Capsule com-bined with conventional western medicine has a certain clinical effect in the treatment of angina pectoris in coronary heart disease,which is worthy of clinical verification by physicians.

Yixinshu(益心舒)CapsuleCoronary heart diseaseAngina pectorisMeta-analysis

张晓刚、赵信科、刘凯、蒋虎刚、王新强、赵晓彬、李倩蓉、李应东

展开 >

甘肃中医药大学,兰州 730000

甘肃中医药大学附属医院,兰州 730020

益心舒胶囊 冠心病、心绞痛 Meta分析

甘肃省中医药循证能力建设项目甘肃省科技重大专项计划

2019XZZX-XXG00220ZD7FA002

2024

中药药理与临床
中国药理学会 四川省中医药科学院

中药药理与临床

北大核心
影响因子:0.996
ISSN:1001-859X
年,卷(期):2024.40(5)